


## CZC-54252 hydrochloride

<b>Cat. No.:</b>	HY-B0792A
<b>CAS No.:</b>	1784253-05-9
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>26</sub> Cl <sub>2</sub> N <sub>6</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	541.45
<b>Target:</b>	LRRK2
<b>Pathway:</b>	Autophagy
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 33.33 mg/mL (61.56 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	1.8469 mL	9.2345 mL	18.4689 mL	
5 mM	0.3694 mL	1.8469 mL	3.6938 mL	
10 mM	0.1847 mL	0.9234 mL	1.8469 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

CZC-54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC<sub>50</sub>s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC<sub>50</sub> of ~1 nM. CZC-54252 hydrochloride has a neuroprotective activity<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 1.28 nM (Wild-type LRRK2) and 1.85 nM (G2019S LRRK2)<sup>[1]</sup>

### REFERENCES

[1]. Nigel Ramsden, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA